• Ticker

    Advertisement Find a Broker - Visit the DailyFinance Broker Center
DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$37.55 -$0.05 (-0.13%)

REAL-TIME: Last trade at

Merck & Co., Inc.

NYSE:MRK

Jump to this page for:

Related Resources

James B Yoseph and Hannah Yoseph, M.D. Announce Their New Book "How Statin Drugs Really Lower Cholesterol (And Kill You One Cell At A Time)"

5/28/2012 by PRWeb

Amylin Said to Get Bids From Sanofi, Merck in First Round of Sale Offers

5/26/2012 by Bloomberg.com

Government of Rwanda Introduces Merck's ROTATEQ® (Rotavirus Vaccine, Live, Oral, Pentavalent) to Help Protect Children Against Rotavirus

5/25/2012 by StockHouse

Government of Rwanda Introduces Merck's ROTATEQ® (Rotavirus Vaccine, Live, Oral, Pentavalent) to Help Protect Children Against Rotavirus

5/25/2012 by StockWatch

Government of Rwanda Introduces Merck's ROTATEQ® (Rotavirus Vaccine, Live, Oral, Pentavalent) to Help Protect Children Against Rotavirus

5/25/2012 by Business Wire

EquipNet to Auction Off Entire Contents of Closed Merck Facility

5/25/2012 by PRWeb

Saving Mothers’ Lives- a collaboration of business, non profits and government

5/24/2012 by Bangor Daily News - Bangor ME

Recent Flurry of New Life Science Funds Aim to Start Bridging the Valley of Death

5/24/2012 by Genetic Engineering News

Merck and Mylan Look to Benefit From Plan to Speed up FDA Reviews

5/24/2012 by Marketwire

Why Abbott Is A Buy After The Lawsuit

5/23/2012 by Seeking Alpha

Hide from Europe's mess with dividend stocks

5/23/2012 by CNNMoney

Merck & Co., Inc. CEO: Singulair, Economy to Make 2012-13 Tough But We Will Survive

5/23/2012 by BioSpace

Merck, American College of Endocrinology Partner on Blood Sugar Basics Game Plan

5/23/2012 by Pharmaceutical and Medical Packaging News

Blood Sugar Basics Game Plan Now Available to Help Patients Tackle Type 2 Diabetes

5/23/2012 by PR Newswire

Pharmaceuticals - Global Group of Eight (G8) Industry Guide

5/23/2012 by PR Newswire

Global pharma

5/22/2012 by FT.com

Codexis Announces Three-Year Extension of Collaboration Agreement with Merck

5/22/2012 by PharmiWeb.com - UK

Merck Announces Third-Quarter 2012 Dividend

5/22/2012 by PharmiWeb.com - UK

Merck 1 Of 4 Interesting Dividend Plays To Consider

5/22/2012 by Seeking Alpha

Merck Announces Third-Quarter 2012 Dividend

5/22/2012 by StockHouse

Merck & Co., Inc. (MRK) Declares $0.42 Quarterly Dividend; 4.5% Yield

5/22/2012 by StreetInsider.com

Merck Announces Third-Quarter 2012 Dividend

5/22/2012 by Business Wire

Analysis And Valuation: Johnson & Johnson, Pfizer, And Merck

5/22/2012 by Seeking Alpha

Merck CEO: Generics, economy to make 2012-13 tough

5/22/2012 by The Boston Globe - Boston MA

Merck CEO: Generics, economy to make 2012-13 tough

5/22/2012 by Bioscience Technology

Merck CEO: Generics, economy to make 2012-13 tough

5/22/2012 by U.S. News & World Report

Merck & Co., Inc. Vaccine Fears Confirmed in Newest Study

5/22/2012 by BioSpace

Merck, Codexis extend collaboration three more years

5/22/2012 by Silicon Valley / San Jose Business Journal - San Jose CA

Codexis and Merck extend collaboration to develop enzyme products

5/22/2012 by Theflyonthewall.com

Codexis Announces Three-Year Extension of Collaboration Agreement with Merck

5/22/2012 by Business Wire

Today's Must Watch Stocks: Wells Fargo, Eaton, Cooper, Merck, Staples, and Seagate

5/22/2012 by PR Newswire

Merck acquires QLight Nanotech stake

5/22/2012 by Globes - Israel

FDA Approves New Labeling For ISENTRESS (raltegravir) To Include 156-Week Data Demonstrating Long-Term Efficacy, Safety And Tolerability With ISENTRESS In Combination Therapy In Previously Untreated Adult Patients Infected With HIV-1

5/22/2012 by Pharmaceutical Online

EFSA Rejects Health Claim for Glucosamine and Joint Cartilage

5/21/2012 by Nutritional Outlook

New study confirms worst fears about Merck's HIV vaccine

5/21/2012 by Fierce Biotech

Merck Animal Health introduces ZUPREVO a new antibiotic for BRD

5/21/2012 by Drovers

FDA Approves New Labeling for ISENTRESS® (raltegravir) to Include 156-Week Data Demonstrating Long-Term Efficacy, Safety and Tolerability with ISENTRESS in Combination Therapy in Previously Untreated Adult Patients Infected with HIV-1

5/21/2012 by PharmiWeb.com - UK

FDA approves new labeling for Merck's ISENTRESS

5/21/2012 by Theflyonthewall.com

Sachs Associates to host a forum

5/21/2012 by Theflyonthewall.com

Outlooks for Pfizer, Arena and Onyx Following Busy May

5/21/2012 by TheStreet.com
See More Articles...